Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.

ABSTRACT:

SUBMITTER: Mascarenhas J 

PROVIDER: S-EPMC6530779 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature